Leo Lens uses its proprietary MediPrint™ process for contact lenses that provide continuous drug delivery
Leo Lens has a proprietary printing technology and ink that allows for the sustained, continuous release of ophthalmic drugs via contact lenses – called the MediPrint™ process. This process yields a new method for treating glaucoma, other eye diseases, and allergies with a non-invasive, cost effective treatment. Drug delivery via a contact lens could have many benefits including improved bioavailability, better patient compliance, and reduced side effects. Further, the innovative MediPrint™ solution mitigates regulatory risks, works seamlessly with existing manufacturing processes, and offers eye care professionals a new treatment method. The value added benefits across the supply chain of manufacturers, eye care professionals, and patients would make it a first line choice for treatment.
While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. There is a large unmet need for a better non-invasive treatment option. Leo Lens is currently focused on advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product pipeline.
Global Glaucoma Market = 70 Million Patients
Over 50 years of research and still no commercial solution for treatment via contact lenses.
Lenses showed sustained release of more than 7 days during in vivo studies.
Concept level clinical evaluation with patients is the next step.
In-vivo sustained release for 7 days
In-vitro sustained release for 10 days
Allergy & Comfort Enhancement
In-vitro sustained release from the same lens for 7 days
Low cost/simple to use
Reduced side effects
Low risk, non-invasive treatment
Better patient outcome
Predictable treatment plan
Fewer complications due to reduced side effects
Reduced cost of medical treatment / Reduced hospitalization
Low cost / high-quality products
Low capital investment
Reduced regulatory complexities
First in the market
Pipeline for multiple products
|Low cost / simple to use||Low risk, non-invasive treatment||Low cost / high quality products|
|Higher bioavailability||Better patient outcome||Low capital investment|
|Better compliance||Predictable treatment plan||Reduced regulatory complexities|
|Reduced side effects||Fewer complications due to reduced side effects||Patent protection|
|Comprehensive solution||Customized prescription||First in the market|
|Non-invasive||Reduced cost for medical treatment / Reduced hospitalization||Pipeline for multiple products|
|Factor||Rationale||Eye Drops||Injection/ Implants||MediPrint™ Contact Lens|
|Eye Care Professional||Who can prescribe to patients||MD/OD||MD||OD/MD|
|Bioavailability for at least 7 days||Continuous delivery. Can avoid fluctuations in IOP for Glaucoma patients||✗||✓||✓|
|Low Manufacturing Cost||Manufacturers require acceptable gross margins to participate in this space||✓||✗||✓|
|High Level of Patient Compliance||Better patient outcomes from improved compliance||✗||✓||✓|
|Easy to Insert and Remove||Non-invasive treatment that is safe and low-cost||✓||✗||✓|
|Can Deliver Multiple Drugs||Customized treatment for patients. Provide lens comfort and treat multiple diseases simultaneously||✗||✓||✓|
|Expedited Regulatory Pathway||505(b)(2)||✗||✗||✓|